Astrana Health (NASDAQ:ASTH) Reaches New 52-Week Low – Time to Sell?

Shares of Astrana Health, Inc. (NASDAQ:ASTH) reached a new 52-week low on Monday . The company traded as low as $31.20 and last traded at $31.35, with a volume of 194714 shares traded. The stock had previously closed at $32.18.

Analyst Ratings Changes

A number of research analysts have recently commented on ASTH shares. Robert W. Baird raised their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. KeyCorp started coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating for the company. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. BTIG Research increased their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Finally, TD Cowen initiated coverage on shares of Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $65.17.

Astrana Health Price Performance

The stock has a market capitalization of $1.78 billion, a P/E ratio of 24.35, a P/E/G ratio of 1.80 and a beta of 1.20. The firm has a fifty day moving average price of $40.97 and a two-hundred day moving average price of $47.24. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. The business had revenue of $478.71 million during the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same period last year, the business earned $0.47 EPS. On average, analysts expect that Astrana Health, Inc. will post 1.16 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ASTH. Janus Henderson Group PLC purchased a new stake in Astrana Health in the third quarter worth approximately $1,164,000. Royce & Associates LP bought a new position in shares of Astrana Health during the 3rd quarter valued at $6,661,000. Amalgamated Bank purchased a new position in shares of Astrana Health in the 3rd quarter worth $713,000. Principal Financial Group Inc. bought a new stake in shares of Astrana Health in the third quarter worth $13,383,000. Finally, Diamond Hill Capital Management Inc. purchased a new stake in Astrana Health during the third quarter valued at $8,245,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.